MDxHealth and PLUS Diagnostics have reached an agreement to co-promote MDxHealth's ConfirmMDx for prostate cancer in the US.
ConfirmMDx is a laboratory-developed test (LDT), which assists urologists with identifying men who may safely forego unnecessary repeat biopsies.
The prostate cancer assay can also identify an epigenetic field effect or halo associated with the cancerization process at the DNA level in cells adjacent to cancer foci.
PLUS Diagnostics CEO David Pauluzzi said, "We believe this test will improve the standard of care for patients with negative prostate biopsies."
The company plans to introduce ConfirmMDx assay in the second quarter of this year.
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients.
